BMAL1 regulates the initial step of embryo implantation by modulating endometrial cell adhesion and migration
Human Cell · 16.06.2026 · 39 (7)
DOI: 10.1007/s13577-026-01386-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Cell, online erschienen am 16.06.2026. Verfasst von Keita Imai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Embryo Implantation, ARNTL Transcription Factors, Cell Adhesion, Cell Movement. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Embryo implantation is a critical and tightly regulated process essential for successful human reproduction. Although the role of endometrial receptivity is well established, the molecular mechanisms governing this process are not thoroughly understood. Circadian rhythm regulators, particularly brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein 1 ( BMAL1 ), have emerged as key modulators in reproductive biology. In this study, we investigated the role of BMAL1 in regulating endometrial receptivity and embryo implantation. Ishikawa cells were transfected with BMAL1 -specific or control siRNA, followed by RT-qPCR, western blotting, and immunofluorescence analyses. Functional assays, including migration assays, co-culture with JEG-3 spheroids, cell viability, and cytotoxicity, were also performed. Our results demonstrated that BMAL1 -knockdown in Ishikawa cells downregulated adhesion-related genes, including ITGAV , ITGB3 , and ITGB5 . Although total ITGB5 protein levels remained stable, its localized expression intensity was significantly reduced; the protein expression of ITGAV and ITGB3 was decreased, and cell migration was impaired. Notably, while BMAL1 -knockdown compromised cellular motility, it had no significant effect on cell viability or cytotoxicity. A co-culture model with JEG-3 spheroids further demonstrated significantly decreased embryo adhesion following BMAL1 -knockdown. In conclusion, BMAL1 is a critical regulator of integrin-mediated adhesion and endometrial receptivity, underscoring its potential as a therapeutic target for recurrent implantation failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan. masanori.a8@keio.jp.
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan. masanori.a8@keio.jp.
- Department of Human Life Environments, Kyoto Notre Dame University, Kyoto, Japan.
- Division of Animal Disease Model, Research Center for Experimental Modeling of Human Disease, Kanazawa University, Kanazawa, Japan.
- Department of Nursing, College of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Imai, K., Dai, Y., Ono, M., Imai, Y., Kojima, J., Fujiwara, T., Daikoku, T., Maida, Y., Ando, H., Fujiwara, H., & Nishi, H. (2026). BMAL1 regulates the initial step of embryo implantation by modulating endometrial cell adhesion and migration. Human Cell, 39(7). https://doi.org/10.1007/s13577-026-01386-0
Vancouver
Imai K, Dai Y, Ono M, Imai Y, Kojima J, Fujiwara T, et al. BMAL1 regulates the initial step of embryo implantation by modulating endometrial cell adhesion and migration. Human Cell. 2026;39(7). doi:10.1007/s13577-026-01386-0
BibTeX
@article{Imai2026,
author = {Imai, Keita and Dai, Yidan and Ono, Masanori and Imai, Yoshinari and Kojima, Junya and Fujiwara, Tomoko and Daikoku, Takiko and Maida, Yoshiko and Ando, Hitoshi and Fujiwara, Hiroshi and Nishi, Hirotaka},
title = {BMAL1 regulates the initial step of embryo implantation by modulating endometrial cell adhesion and migration},
journal = {Human Cell},
year = {2026},
volume = {39},
number = {7},
doi = {10.1007/s13577-026-01386-0}
}
EUVIMED